Milestone Pharma's Etripamil Nasal Spray MAA Accepted by EMA for PSVT

summarizeSummary

Milestone Pharmaceuticals announced the European Medicines Agency (EMA) accepted its Marketing Authorization Application for etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT), with a decision expected by Q1 2027. This marks a significant step towards expanding the product's market beyond its existing FDA approval.

check_boxKey Events

• EMA MAA Acceptance

  The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for etripamil nasal spray.

• Target Indication

  Etripamil is developed for the treatment of paroxysmal supraventricular tachycardia (PSVT).

• Regulatory Timeline

  A decision on approval from the EMA is anticipated by the first quarter of 2027.

• Market Expansion Potential

  If approved, etripamil (conditionally branded TACHYMIST™ in Europe) would address an estimated two million PSVT patients in Europe, building on its existing FDA approval (CARDAMYST™) in the U.S.

auto_awesomeAnalysis

This event is a crucial step for Milestone Pharmaceuticals to expand its flagship product, etripamil, into the European market. The acceptance of the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) indicates that the application is complete and has entered the formal review process, which is a positive signal for the company's commercial prospects. Given that etripamil is already FDA-approved in the U.S., this European expansion could significantly increase the product's addressable market and revenue potential. Investors should monitor the EMA's review process and the anticipated decision in Q1 2027, as European approval would be a major catalyst for the stock.